Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO1 | P15559 | 1/20 | 0.59 |
| ▸ | HPGDS | O60760 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.55 |
| ▸ | SNCA | P37840 | 1/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.51 |
| ▸ | HTR3A | P46098 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | AR | P10275 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | HTR1D | P28221 | 1/20 | 0.45 |
| ▸ | HTR1B | P28222 | 1/20 | 0.45 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.44 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31499214 | 0.96 | NQO1 (0.62) | NQO1HPGDSCYP1A2CYP2A6SNCA | |
| SCHEMBL906936 | 0.96 | NQO1 (0.62) | NQO1HPGDSCYP1A2CYP2A6SNCA | |
| SCHEMBL29098896 | 0.93 | CYP1A2 (0.68) | NQO1HPGDSCYP1A2CYP2A6SNCA | |
| SCHEMBL2233702 | 0.83 | APP (0.53) | NQO1HPGDSSNCASLC6A2SLC6A4 | |
| SCHEMBL7341254 | 0.82 | AR (0.56) | NQO1HPGDSCYP1A2CYP2A6SNCA | |
| SCHEMBL13098025 | 0.81 | CYP11B1 (0.51) | NQO1HPGDSSNCAMEN1KMT2A | |
| SCHEMBL443528 | 0.81 | CYP2A6 (0.80) | NQO1CYP1A2CYP2A6MEN1KMT2A | |
| SCHEMBL29367032 | 0.81 | CYP2A6 (0.80) | NQO1CYP1A2CYP2A6MEN1KMT2A | |
| SCHEMBL29489123 | 0.81 | CYP2A6 (0.52) | CYP2A6SLC6A2SLC6A4SLC6A3HTR3A | |
| SCHEMBL1341822 | 0.81 | CYP2A6 (0.52) | CYP2A6SLC6A2SLC6A4SLC6A3HTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7001900-B2 | Azabicyclic compounds for the treatment of disease | PFIZER INC. (US) | 2006-02-21 | — | — | US | disclosed |
| EP-1070714-A9 | AMIDINE COMPOUNDS | JAPAN TOBACCO INC. (JP) | 2005-10-19 | — | — | EP | disclosed |
| US-20050014789-A1 | Amide derivatives as selective serotonin re-uptake inhibitors | PFIZER INC | 2005-01-20 | — | — | US | disclosed |
| WO-2004111003-A1 | AMIDE DERIVATIVES AS SELECTIVE SEROTONIN RE-UPTAKE INHIBITORS | PFIZER LIMITED (GB) | 2004-12-23 | — | — | WO | disclosed |
| EP-1478646-A1 | AZABICYCLIC COMPOUNDS WITH ALFA7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | PHARMACIA & UPJOHN COMPANY (US) | 2004-11-24 | — | — | EP | disclosed |
| EP-1070714-B1 | AMIDINE COMPOUNDS | JAPAN TOBACCO INC (JP) | 2004-08-04 | — | — | EP | disclosed |
| EP-1419162-A1 | SUBSTITUTED-ARYL 7-AZA 2.2.1]BICYCLOHEPTANES FOR THE TREATMENT OF DISEASE | Pharmacia & Upjohn Company (US) | 2004-05-19 | — | — | EP | disclosed |
| US-20040006099-A1 | Amidine compounds | JAPAN TOBACCO INC. | 2004-01-08 | — | — | US | disclosed |
| US-20030236270-A1 | Azabicyclic compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | disclosed |
| WO-2003072578-A1 | AZABICYCLIC COMPOUNDS WITH ALFA7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | PHARMACIA & UPJOHN COMPANY (US) | 2003-09-04 | — | — | WO | disclosed |
| US-6284796-B1 | NAPHTHAMIDINE COMPOUNDS | ABBOTT LABORATORIES | 2001-09-04 | — | — | US | disclosed |
| CN-1305470-A | Amidine compounds | JAPAN TOBACCO INC (JP) | 2001-07-25 | — | — | CN | disclosed |
| US-6258822-B1 | ENZYME INHIBITORS OF NAPHTHALENE AMIDINE COMPOUNDS | ABBOTT LABORATORIES | 2001-07-10 | — | — | US | disclosed |
| EP-1070714-A1 | AMIDINE COMPOUNDS | JAPAN TOBACCO INC. (JP) | 2001-01-24 | — | — | EP | disclosed |
| US-6121309-A | SUCH AS 4-(2-(5-(7-FLUORO-4-TRIFLUOROMETHYLBENZOFURAN-2-YL)PYRROLYL)) BENZOIC ACID; RETINOIC ACID RECEPTOR AGONISM | EISAI CO., LTD. (JP) | 2000-09-19 | — | — | US | disclosed |
| US-6110959-A | A RETINOIC ACID RECEPTOR AGONIST | EISAI CO., LTD. (JP) | 2000-08-29 | — | — | US | disclosed |
| EP-1000018-A2 | UROKINASE INHIBITORS | Abbott Laboratories (US) | 2000-05-17 | — | — | EP | disclosed |
| WO-1999005096-A2 | UROKINASE INHIBITORS | ABBOTT LABORATORIES (US) | 1999-02-04 | — | — | WO | disclosed |
| EP-0889032-A1 | FUSED-RING CARBOXYLIC ACID DERIVATIVES | Eisai Co., Ltd. (JP) | 1999-01-07 | — | — | EP | disclosed |
| WO-1997036865-A1 | PROCESS FOR PRODUCING INTERMEDIATE COMPOUNDS FOR THE PRODUCTION OF FACTOR Xa INHIBITORS | BOEHRINGER MANNHEIM GMBH (DE) | 1997-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236270-A1 | Azabicyclic compounds for the treatment of disease | MALT1, TPMT, CYP2B6 | NQO1 583/4885HPGDS 1600/4885CYP1A2 74/4885 |
| US-20040006099-A1 | Amidine compounds | F2, SERPINC1, F12 | NQO1 757/4885HPGDS 1095/4885CYP1A2 150/4885 |
| US-20050014789-A1 | Amide derivatives as selective serotonin re-uptake inhibitors | SLC6A4, HTR3C, HTR3A | NQO1 2251/4885HPGDS 2312/4885CYP1A2 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.